Login to Your Account

IV Route Could Complicate Picture

Tysabri's Physician Uptake Remains Question Mark

By Randall Osborne

Monday, November 29, 2004

Earlier this month when Biogen Idec Inc. at last unveiled one-year data from its Phase III trial known as AFFIRM, hopes of investors - not to mention multiple sclerosis patients - ran high for the would-be blockbuster Antegren (natalizumab).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription